ETrade Capital Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
$3.67M Buy
58,075
+17,064
+42% +$1.18M 0.07% 146
2020
Q2
$3.15M Sell
41,011
-45,726
-53% -$3.5M 0.07% 155
2020
Q1
$6.49M Buy
86,737
+35,028
+68% +$2.42M 0.17% 72
2019
Q4
$3.36M Sell
51,709
-6,747
-12% -$439K 0.08% 143
2019
Q3
$3.71M Buy
58,456
+45,485
+351% +$2.97M 0.09% 131
2019
Q2
$876K Sell
12,971
-4,294
-25% -$282K 0.02% 381
2019
Q1
$1.12M Sell
17,265
-8,948
-34% -$595K 0.03% 303
2018
Q4
$1.64M Sell
26,213
-780
-3% -$54.5K 0.05% 205
2018
Q3
$2.08M Buy
26,993
+9,748
+57% +$736K 0.06% 191
2018
Q2
$1.22M Sell
17,245
-14,841
-46% -$1.05M 0.04% 296
2018
Q1
$2.42M Sell
32,086
-1,998
-6% -$159K 0.08% 148
2017
Q4
$2.44M Sell
34,084
-697
-2% -$52.9K 0.08% 146
2017
Q3
$2.82M Buy
34,781
+419
+1% +$32K 0.1% 113
2017
Q2
$2.43M Buy
34,362
+345
+1% +$23K 0.09% 124
2017
Q1
$2.31M Sell
34,017
-1,348
-4% -$94.8K 0.1% 128
2016
Q4
$2.53M Buy
35,365
+2,186
+7% +$162K 0.12% 105
2016
Q3
$2.63M Sell
33,179
-3,043
-8% -$247K 0.13% 90
2016
Q2
$3.02M Sell
36,222
-9,620
-21% -$854K 0.16% 69
2016
Q1
$4.21M Buy
45,842
+443
+1% +$40K 0.24% 39
2015
Q4
$4.59M Buy
45,399
+1,150
+3% +$120K 0.27% 37
2015
Q3
$4.34M Buy
44,249
+1,303
+3% +$145K 0.27% 37
2015
Q2
$5.03M Buy
42,946
+220
+0.5% +$24K 0.3% 31
2015
Q1
$4.19M Buy
42,726
+2,439
+6% +$248K 0.25% 41
2014
Q4
$3.8M Buy
40,287
+4,412
+12% +$456K 0.23% 39
2014
Q3
$3.82M Sell
35,875
-571
-2% -$55.9K 0.25% 37
2014
Q2
$3.02M Buy
36,446
+2,833
+8% +$221K 0.2% 55
2014
Q1
$2.38M Buy
33,613
+5,782
+21% +$453K 0.17% 66
2013
Q4
$2.09M Buy
27,831
+5,791
+26% +$403K 0.17% 71
2013
Q3
$1.39M Buy
22,040
+4,772
+28% +$285K 0.13% 84
2013
Q2
$886K Buy
+17,268
New +$900K 0.09% 111

Other funds holding GILD

ETrade Capital Management's GILD Position: Q3 2020 in Review

ETrade Capital Management increased its Gilead Sciences (GILD) stake by 42% in Q3 2020, buying an estimated $1.18M and bringing the position to 58,075 shares worth $3.67M. The position accounts for 0.07% of the portfolio, ranked #146.

ETrade Capital Management first reported a position in GILD in Q2 2013 and has held it in 30 quarters since. The position peaked at $6.49M in Q1 2020. 1,539 funds tracked by Wall St. Rank hold GILD as of Q3 2020.

  • ETrade Capital Management held 58,075 shares of Gilead Sciences worth $3.67M as of Q3 2020.
  • ETrade Capital Management bought 17,064 Gilead Sciences shares in Q3 2020, an estimated $1.18M.
  • Gilead Sciences made up 0.07% of ETrade Capital Management's portfolio in Q3 2020, its #146 holding.
  • ETrade Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 30 quarters since.
  • ETrade Capital Management's Gilead Sciences position peaked at $6.49M in Q1 2020.
  • 1,539 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.